Cibinetide - Araim Pharmaceuticals

Drug Profile

Cibinetide - Araim Pharmaceuticals

Alternative Names: ARA 290

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Araim Pharmaceuticals
  • Developer Araim Pharmaceuticals; Karolinska Institute; National Institute on Aging; Queens University Belfast
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Peptides
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Neuropathic pain; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Depressive disorders; Diabetic macular oedema; Diabetic neuropathies; Neuropathic pain; Rheumatoid arthritis; Type 2 diabetes mellitus
  • Preclinical Inflammatory bowel diseases; Retinal disorders; Systemic lupus erythematosus; Transplant rejection; Wounds
  • No development reported Radiation injuries

Most Recent Events

  • 16 May 2018 Preclinical trials in Inflammatory bowel disease in USA before May 2018
  • 16 May 2018 Preclinical trials in Systemic lupus erythematosus in USA before May 2018
  • 16 May 2018 Pharmacodynamics data from a preclinical trials in Inflammatory bowel disease and Systemic lupus erythematosus released by Araim Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top